Full-Time
Software Development
1, Engineering
Boston Scientific
10,001+ employees
Medical devices maker for interventional specialties
Compensation Overview
$61k - $115.9k/yr
No H1B Sponsorship
Waltham, MA, USA
Hybrid
Three to four days per week in-office required.
 Software Engineering (1) |
|---|
- Bachelor of Science degree in Computer Science.
- Must have prior intern/co-op experience with Boston Scientific.
- Must be eligible to work in the United States without company sponsorship for employment-based work authorization.
- Must have at least 0-1 year of experience in Software Test Engineering at Boston Scientific.
- Design, develop and release innovative high-performance medical device software.
- Solve difficult problems and always strive to make things better and achieve engineering excellence.
- Partner with other teams including marketing, systems engineering, QA, hardware and regulatory to understand requirements and bring the best solutions forward.
- Continuously improves process and work methodologies by interfacing with peers/cross-functional groups and analyzing activities to improve workflow and work processes.
- Working knowledge of C, Linux, and/or C++ is highly desirable.
- Strong experience with designing and implementing medical device software.
- Strong experience with the development of network protocols (TCP/IP, HTTP, OpenSSL).
- Experience in Object-Oriented programming.
Boston Scientific designs and makes medical devices used in procedures across cardiology, endoscopy, urology, and neuromodulation. Its products help doctors diagnose and treat conditions by guiding minimally invasive interventions and delivering therapies inside the body, with revenue from hospitals and clinics. The firm differentiates itself through a broad, global portfolio and heavy ongoing investment in research and development to expand capabilities and address complex health issues. Its goal is to improve patient care by providing reliable, effective medical devices and solutions that enable clinicians to perform safer, more effective procedures while growing its business.
Company Size
10,001+
Company Stage
IPO
Headquarters
Marlborough, Massachusetts
Founded
1979
Your Connections
People at Boston Scientific who can refer or advise you
Simplify's Take
What believers are saying
- SEISMIQ 4CE enables 100% stent delivery with optimal expansion in calcified lesions[2].
- CHAMPION trial met all endpoints, supporting WATCHMAN safety and efficacy for stroke prevention[6].
- SIMPLAAFY trial enrollment completed; results expected H2 2026 to expand LAAC market further[6].
What critics are saying
- Medtronic and Johnson & Johnson capture PFA share faster than anticipated in 2026, eroding electrophysiology growth[Negative trends].
- Bolt Medical acquisition risks trial delays and pricing pressure on SEISMIQ catheter from Johnson & Johnson competition[Negative trends].
- WATCHMAN faces flat dollar growth through Q3 2026 due to declining standalone procedures and hospital capacity constraints[Negative trends].
What makes Boston Scientific unique
- SEISMIQ 4CE catheter achieved 93.7% procedural success in calcified coronary disease trial[1][2].
- Boston Scientific invests $138M building Indiana distribution center to boost global logistics[1].
- WATCHMAN platform grew 19% in Q1 2026, expanding patient pool from 5M to 20M[6].
Help us improve and share your feedback! Did you find this helpful?
Benefits
Relocation Assistance
Performance Bonus
Growth & Insights and Company News
6 month growth
↑ 11%1 year growth
↑ 11%2 year growth
↑ 12%Class action launched over alleged defects in pacemakers. A new proposed Canadian class action alleges that certain Boston Scientific pacemakers may pose serious health risks due to potential battery defects and device failures. On June 9, 2026, Siskinds Desmeules, Siskinds LLP's Québec affiliate, filed an application in the Superior Court of Québec seeking authorization to represent Canadians implanted with specific pacemakers who suffered injury or may require premature device replacement. Reported longstanding battery issues with Boston Scientific devices can trigger failures. A March 2026 New York Times investigation reported that Boston Scientific was aware over a period of years of potential battery performance issues in certain pacemakers, including the Accolade and Ingenio lines, based on internal records and regulatory inspection findings, while continuing to investigate their causes and scope. The report described how manufacturing problems and inadequate analysis of battery testing data between 2013 and 2021, along with later-identified issues, may have contributed to defective devices remaining in circulation, with battery-related failures linked to at least seven deaths and more than 800 injuries. The affected products have been subject to multiple recalls and safety advisories, including large-scale actions ultimately affecting more than 1.6 million devices worldwide due to battery-related malfunctions that can trigger Safety Mode activation. Device failures may lead to serious and life-threatening complications. The newly filed application to authorize a class action alleges that design and/or manufacturing defects in certain Boston Scientific devices' internal batteries may increase electrical resistance and trigger an irreversible "Safety Mode." This mode can impair the pacemaker's ability to regulate heart rhythm in accordance with individual patients' requirements and may require surgical replacement. Such failures may result in a loss of effective pacing, particularly in patients who depend on the device. According to the claim, potential complications include irregular heart rhythms, fainting and fall-related injuries, worsening heart failure, stroke or heart attack, surgical complications, and death. Some patients may require urgent medical intervention, including device replacement. The Boston Scientific pacemaker and CRT-P models at issue include Accolade, Altrua, Essentio, Proponent, Valitude, Visionist, Advantio, Ingenio, Vitalio, Invive, Inliven, and Intua. Siskinds seeks justice for patients implanted with Boston Scientific pacemakers. Siskinds LLP is seeking compensation for Canadians who were implanted with one of the impacted devices. The action aims to address physical, emotional, and financial losses suffered by patients who experienced bodily injury, as well as those requiring ongoing monitoring or experiencing harm related to the risk of failure. If you or someone you know has received a Boston Scientific pacemaker, you may be impacted by the proposed class action. Contact Siskinds at [email protected], visit siskinds.com/pacemakers and click the join button, or call 1.800.461.6166 for more information. James is an associate lawyer in the class actions department. His practice is focused on class action litigation, including medical and product liability class actions. James has been selected for inclusion in the 2025 and 2026 editions of Best Lawyers: Ones to Watch in Canada(TM) list which recognizes Canadian lawyers who are earlier in their careers for outstanding professional excellence. Jordyn is an associate practicing in the areas of class actions and medical negligence litigation. Receive blog posts. If you'd like to receive an email when a new post is added to its blog, let Siskinds LLP know. News & views. Blog. The more you understand, the easier it is to manage well. A not so 'thrilling' management: A discussion of estate trustee duties and responsibilities within the context of the Michael Jackson Estate. Recently, the management of Michael Jackson's Estate has made headlines in the news. Specifi... Understanding jurisdictional challenges in British Columbia class actions. Jurisdictional challenges are increasingly shaping the landscape of Canadian class actions,...
Customizing clinical trial content for Boston Scientific's device trials. Clinical Research Boston Scientific, a global leader in medical device innovation, was seeking support for developing new education materials that better engaged and increased participation from patients historically underrepresented in U.S. medical device clinical trials. Through partnering with CISCRP, Boston Scientific successfully customized eight brochures for use in device trials, demonstrating the value and adaptability of CISCRP's codeveloped, user-tested educational content for sponsor-specific needs. Key Service Content licensing & brochure customization About Boston Scientific. Boston Scientific is a global medical device manufacturer dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world. The challenge. Boston Scientific recognized a need for developing new clinical trial education materials with a particular focus on improving enrollment of historically underrepresented patient populations. However, existing educational materials were often not tailored to the specific nuances of device trials or the diverse communities they aimed to reach. The content needed to include comprehensive, plain language that would resonate with patients, meet regulatory requirements, and maintain the highest standards of clarity and accessibility across different demographics and cultures. The solution. Boston Scientific partnered with CISCRP to leverage its library of patient-friendly, clinical research content. After evaluating available content and considering their unique needs, Boston Scientific selected CISCRP's customizable, educational materials for adaptation. The collaboration focused on tailoring these resources specifically for device trials, utilizing CISCRP's health literacy expertise and team of project management, medical writing, community engagement and graphic design. As a result, Boston Scientific was able to provide culturally-sensitive, unbiased, and patient-friendly materials that met industry standards and regulatory requirements. The results. With CISCRP's support, Boston Scientific successfully repurposed and adapted eight brochures to address questions and information most relevant to patients considering enrolling in a medical device clinical trial. All materials received IRB-approval and were validated for cultural appropriateness across patient populations. Over 500 community members participated in user testing, ensuring the highest standards of comprehension and accessibility. The initiative enabled Boston Scientific to improve patient engagement and representation in their clinical trials with education materials tailored to medical devices and those who have been historically underrepresented within the U.S. - demonstrating the impact and versatility of CISCRP's co-developed educational resources.
Boston Scientific announces €75 million investment to expand R&D capabilities in Galway. 15/04/2026 Ireland GALWAY, IRELAND (15 April 2026) - Boston Scientific Corporation (NYSE: BSX) - a global leader in medical device technology - today announced a €75 million investment in its Galway site, including the expansion of its research and development (R&D) capabilities, further strengthening its role as a global centre for cardiovascular innovation. The development, which is supported by funding from the Irish government through IDA Ireland, includes purpose-built laboratories to enhance the ability of teams in Galway to design, develop and test next-generation medical technologies across a range of cardiovascular therapies. The expanded capability will support priority programmes across structural heart, cardiovascular and endoscopy, as well as emerging areas such as heart failure and renal denervation technologies, underpinned by a strong regional talent base and STEM ecosystem. Regarding the announcement, Minister for Education and Youth, Hildegarde Naughton said: "The decision by Boston Scientific to invest again in Galway shows real confidence in the talent and infrastructure available here. The importance of R&D and innovation to Ireland's economy cannot be overstated. It is achieved through a strong partnership between industry, Government and IDA Ireland and has acknowledged that Galway is now an internationally recognised MedTech hub. This is due in no small part to the presence of Boston Scientific, one of the largest life sciences employers in the country, and I want to very much thank them for their continued investment." Minister for Enterprise, Tourism and Employment, Peter Burke said: "This €75 million investment by Boston Scientific is a strong vote of confidence in Galway, in Ireland's life sciences ecosystem, and in the highly skilled workforce that underpins it. Expanding R&D capability in this way strengthens Ireland's role as a global hub for medical technology innovation and supports the development of life changing treatments for patients worldwide. The Government is committed to supporting companies like Boston Scientific as they continue to scale, innovate and create high value employment across the regions." As a global leader in medical technology innovation, Boston Scientific continues to invest in capabilities that advance patient care, with Galway playing a key role in delivering that innovation. "We are seeing strong momentum across our cardiovascular business, and this investment reflects the important role the Galway site plays in that progress," said Lance Bates, executive vice president and president, Interventional Cardiology and Vascular Therapies, Boston Scientific. "The local team is delivering complex, highly collaborative work that is advancing meaningful innovation for patients. The strength of the site, the talent in Ireland and the support of the Irish Government and IDA Ireland give us confidence to continue investing in our future growth." Boston Scientific has a long-established presence in Ireland spanning over 30 years, with over 7,000 employees across sites in Galway, Cork and Clonmel producing over 30 million devices each year for patients worldwide. Medical devices exported from the Galway facility every year include drug-coated devices, vascular balloons and heart and oesophageal stents. These products help treat patients with conditions including heart disease, vascular disease, oesophageal cancer and those at risk of stroke. Rachel Shelly, Global Head of Life Sciences at IDA Ireland, stated: "Boston Scientific's €75 million R&D investment in Galway reinforces Ireland's leadership in medical technology innovation. For more than 30 years, Boston Scientific has invested in advanced manufacturing and innovative technologies in Ireland, benefiting patients, communities and ecosystems locally and globally. IDA Ireland looks forward to continued collaboration with Boston Scientific to advance MedTech excellence." You might also be interested in. Klaviyo invests in engineering hub in Ireland. New senior engineering roles in Dublin put Irish talent at the centre of a platform delivering personalised customer experiences for 193,000 consumer brands worldwide Prove accelerates global innovation with expansion of Ireland R&D hub. $5M investment and expanded Dublin team accelerates product strategy and supports Prove's growing global customer base
Boston Scientific has raised $120 million in Series C funding at a $1.45 billion valuation, led by Ribbit Capital with participation from Sequoia, Kleiner Perkins and new backer Emerson Collective. The pre-revenue AI startup, co-founded by Robinhood CEO Vlad Tenev, is developing "Mathematical Superintelligence" to eliminate AI hallucinations through formal reasoning. Its Aristotle model requires outputs in Lean4 programming language, enabling verification for correctness. The model achieved top performance at the International Mathematical Olympiad in July. Founded in 2023, Boston Scientific has raised $295 million across three rounds in 14 months. The company offers Aristotle via free API and targets commercialisation in safety-critical sectors including aerospace, finance and automotive.
Boston Scientific presents Watchman FLX and EKOS endovascular system data. Boston presented the pair of trial readouts at the 2026 American College of Cardiology (ACC) conference in New Orleans. Boston Scientific has shared a duo of positive data readouts from two separate trials evaluating its Watchman FLX left atrial appendage closure (LAAC) device in non-valvular atrial fibrillation (AF) patients, and its EKOS endovascular system in patients with intermediate-risk pulmonary embolism (PE). The Watchman trial evaluated whether the device represented a reasonable alternative to non-vitamin K oral anticoagulants (NOACs) in patients with non-valvular AF, while the Ekos trial evaluated whether the endovascular system was superior to the current standard of care (SoC) - anticoagulation alone - in treating patients with acute PE. The results from each study were shared during the 2026 American College of Cardiology (ACC) conference, which took place from 28 to 30 March in New Orleans, Louisiana. The findings from each study were also simultaneously published in The New England Journal of Medicine. In the 3,000-patient CHAMPION-AF (NCT04394546) trial, Watchman met its primary safety endpoint as a first-line option for stroke risk reduction in patients with non-valvular AF. The device proved statistically superior to NOACs at the three-year readout, achieving a 45% relative reduction in non-procedural bleeding risk. The study's primary efficacy endpoint, defined as the occurrence of stroke, cardiovascular or unexplained death or systemic embolism, was met, with Watchman achieving statistical non-inferiority compared to NOACs at 5.7% versus 4.8%. Including procedural bleeding in a secondary analysis, Watchman was consistent with the primary safety endpoint and demonstrated a significant reduction in bleeding compared to NOACs, representing a 34% relative reduction in procedural and non-procedural bleeding risk. "These positive data, which have the potential to support updated clinical guidelines globally, will be used in our submission to expand the indication and coverage for the well-established Watchman platform as a first-line stroke risk reduction option, providing physicians with more choices in care for a wider range of patients who have atrial fibrillation," said Brad Sutton, chief medical officer, atrial fibrillation solutions at Boston Scientific. "Today, 40% of patients with AF who are prescribed blood thinners for stroke risk reduction are not taking their medications consistently, significantly increasing their risk of stroke," Sutton added. Boston's Watchman franchise represents a key revenue driver within the company's cardiovascular portfolio. In Q4 2025, the franchise achieved a 29.4% uptick on its Q4 2024 performance, contributing $535m to Boston's $3.4bn revenue performance in Q4 2025. In the 544-patient HI-PEITHO trial (NCT04790370), Boston's Ekos system's delivery of a low dose of clot-dissolving medication directly to the blood clot to facilitate the dispersion of the medication deep into the clot to dissolve it was compared against the SoC of anticoagulation alone. Meeting the trial's co-primary endpoint of PE-related mortality, non-fatal hemodynamic cardiorespiratory decompensation or collapse and non-fatal symptomatic recurrence of PE within seven days, Ekos plus anticoagulation demonstrated superiority to anticoagulation alone at 4% versus 10.3%, representing a 61% reduction in the primary endpoint events. This result was achieved with no episodes of bleeding within the brain through 30 days. Dr Michael Jaff, vice president and chief medical officer, vascular therapies at Boston Scientific, said: "The HI-PEITHO trial evaluated clear, clinically meaningful endpoints using rigorous patient enrolment criteria and demonstrated a definitive impact with the Ekos system over the standard of care for treating acute PE. "For the first time, we have robust randomised clinical trial data available to inform treatment decisions by interventionalists and referring physicians and support consideration of Ekos plus anticoagulation as a first-line therapy." Give your business an edge with its leading industry insights.